School of Immunology and Microbial Sciences, King's College London, London, UK.
NIHR Biomedical Research Centre at Guy's and Saint Thomas' NHS Foundation Trust and King's College, London, UK.
Gut. 2020 May;69(5):942-952. doi: 10.1136/gutjnl-2019-319850. Epub 2020 Jan 24.
The prevalence of IBD is rising in the Western world. Despite an increasing repertoire of therapeutic targets, a significant proportion of patients suffer chronic morbidity. Studies in mice and humans have highlighted the critical role of regulatory T cells in immune homeostasis, with defects in number and suppressive function of regulatory T cells seen in patients with Crohn's disease. We review the function of regulatory T cells and the pathways by which they exert immune tolerance in the intestinal mucosa. We explore the principles and challenges of manufacturing a cell therapy, and discuss clinical trial evidence to date for their safety and efficacy in human disease, with particular focus on the development of a regulatory T-cell therapy for Crohn's disease.
炎症性肠病在西方世界的发病率正在上升。尽管治疗靶点不断增加,但仍有相当一部分患者患有慢性疾病。在小鼠和人类中的研究强调了调节性 T 细胞在免疫稳态中的关键作用,在克罗恩病患者中观察到调节性 T 细胞数量和抑制功能缺陷。我们综述了调节性 T 细胞的功能以及它们在肠道黏膜中发挥免疫耐受的途径。我们探讨了制造细胞疗法的原则和挑战,并讨论了迄今为止这些疗法在人类疾病中的安全性和疗效的临床试验证据,特别关注用于治疗克罗恩病的调节性 T 细胞疗法的开发。